T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial

Dimitrios Karussis, Hagai Shor, Julia Yachnin, Naama Lanxner, Merav Amiel, Keren Baruch, Yael Keren-Zur, Ofra Haviv, Massimo Filippi, Panayiota Petrou, Shalom Hajag, Urania Vourka-Karussis, Adi Vaknin-Dembinsky, Salim Khoury, Oded Abramsky, Henri Atlan, Irun R. Cohen, Rivka Abulafia-Lapid

Research output: Contribution to journalArticlepeer-review

Abstract

Background: T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled. Aim: To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind, controlled clinical trial. Methodology: Twenty-six patients with relapsing-progressive MS were enrolled in the study (mean age: 39±9.8 years; mean EDSS: 4.4±1.7). T-cell lines reactive to 9 different peptides of the myelin antigens, MBP, MOG and PLP were raised from the patients' peripheral blood. The patients were randomized into two groups: 19 were treated with TCV (four subcutaneous injections of 10-30×106 T-cells, attenuated by irradiation, on days 1, 30, 90 and 180) and 7 patients were treated with sham injections. Twenty-four patients (17 in the TCV group and 7 in the placebo) were eligible for per-protocol analysis. Results: At one year following the inclusion, an increase in the EDSS (+0.50) and an increase in 10-meter walking time (+0.18 sec), were observed in the placebo group; in the TCV group there was a decrease in the EDSS (-0.44; p

Original languageEnglish
Article numbere50478
JournalPLoS One
Volume7
Issue number12
DOIs
Publication statusPublished - Dec 14 2012

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint

Dive into the research topics of 'T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial'. Together they form a unique fingerprint.

Cite this